ClinicalTrials.gg
RecruitingNCT07020221Updated Nov 10, 2026

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

A Phase 1/2 interventional study of VS-7375 and Cetuximab in Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer and Colorectal Cancer, sponsored by Verastem, Inc.. Recruiting at 22 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Verastem, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.
Updated Nov 10, 2026First sites in France and SpainEnrollment updated+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
616
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
197th of 2,998
616 · median 56
Started
2025
with 148 others
Phase 1/2
486 of 3,371
119 open now
Primary completion
2028-12
later than 669 of 892 live
Registered
3,179th of 3,371
by date

Among the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 197th largest by planned enrollment of the 2,998 interventional ones that give a count, is one of 149 that started in 2025, is one of 486 in phase 1/2, reaches primary completion later than 669 of the 892 other live ones, and was the 3,179th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

521 of the 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

516 more — sign in →

All 521 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,371 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

03

Conditions studied

  • Pancreatic Ductal Adenocarcinoma
  • Non Small Cell Lung Cancer
  • Colorectal Cancer
  • Solid Tumor, Adult
  • G12D Mutated KRAS

Keywords

  • KRAS G12D mutation
  • Solid tumors
  • Non Small Cell Lung Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Metastatic Cancer
  • Pancreatic Cancer
  • Pancreatic Ductal Adenocarcinoma
  • NSCLC
  • CRC
  • PDAC
  • Pancreatic Neoplasms
  • Colorectal Neoplasms
  • Lung Neoplasms
  • Gastrointestinal Neoplasms
  • KRAS
  • RAS
  • Biliary Tract Cancer
  • BTC
  • Biliary Tract Neoplasms
  • Intrahepatic cholangiocarcinoma
  • Appendiceal Cancer
  • Endometrial Cancer
  • Small bowel Cancer
04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Individuals ≥18 years of age.
  • Agreement to sign and date an form (ICF) approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).
  • Histologic or cytologic evidence of locally advanced unresectable or solid tumor harboring a KRAS G12D mutation.
  • according to (RECIST) v1.1.
  • (ECOG) performance status 0 or 1
  • Adequate organ function
  • Adequate cardiac function
  • Recovered from all AEs due to previous therapies to Grade ≤1 or baseline
  • Agreement to use highly effective

Key Exclusion Criteria:

  • Underwent major surgical procedure as defined by the Investigator, other than for diagnosis, within 4 weeks prior to Cycle 1 Day 1
  • Receipt of chemotherapy, targeted therapy, or radiotherapy (excluding palliative radiation) within 4 weeks or 5 half-lives, whichever is shorter, or immunotherapy within 4 weeks prior to Cycle 1 Day 1.
  • Treatment with any drug at least 4 weeks or 5 half-lives, whichever is shorter, prior to Cycle 1 Day 1.
  • History of treatment with direct RAS inhibitors.
  • Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases.
  • Inability to swallow oral medications.
  • Evidence or history of uncontrolled, hematological, renal, hepatic, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, coagulation, neurologic, dermatologic, , or allergic disease.
  • Individuals who are pregnant or breastfeeding.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
616 participants (estimated)

Study arms

  • Experimental
    VS-7375 Monotherapy Dose Escalation

    To characterize the safety and tolerability of escalating doses of VS-7375 as monotherapy and to determine the recommended phase 2 dose (RP2Ds) in patients with advanced solid tumors harboring KRAS G12D mutation.

    Drug: VS-7375

  • Experimental
    VS-7375 Monotherapy Dose Expansion - PDAC

    To evaluate the efficacy of VS-7375 at the recommended phase 2 dose (RP2Ds) in patients with metastatic PDAC harboring KRAS G12D-mutation.

    Drug: VS-7375

  • Experimental
    VS-7375 Monotherapy Dose Expansion - NSCLC

    To evaluate the efficacy of VS-7375 at the recommended phase 2 dose (RP2Ds) in patients with metastatic NSCLC harboring KRAS G12D-mutation.

    Drug: VS-7375

  • Experimental
    VS-7375 Monotherapy Dose Expansion - Solid Tumors

    To evaluate the efficacy of VS-7375 at the recommended phase 2 dose (RP2Ds) in patients with metastatic solid tumors harboring KRAS G12D-mutation.

    Drug: VS-7375

  • Experimental
    VS-7375 + Cetuximab Dose Escalation

    To characterize the safety and tolerability of escalating doses of VS-7375 in combination with cetuximab and to determine the recommended phase 2 dose (RP2Ds) in patients with advanced or metastatic PDAC, BTC, CRC harboring KRAS G12D-mutation.

    Drug: VS-7375 · Drug: Cetuximab

  • Experimental
    VS-7375 + Carboplatin/Pemetrexed/Pembrolizumab Dose Escalation

    To characterize the safety and tolerability of escalating doses of VS-7375 in combination with carboplatin/pemetrexed/pembrolizumab and to determine the recommended phase 2 dose (RP2Ds) in patients with metastatic NSCLC harboring KRAS G12D-mutation.

    Drug: VS-7375 · Drug: Carboplatin + Pemetrexed + Pembrolizumab

  • Experimental
    VS-7375 + Gemcitabine/Nab-Paclitaxel Dose Escalation

    To characterize the safety and tolerability of escalating doses of VS-7375 in combination with gemcitabine/nab-paclitaxel and to determine the recommended phase 2 dose (RP2Ds) in patients with advanced or metastatic PDAC harboring KRAS G12D-mutation.

    Drug: VS-7375 · Drug: Gemcitabine + Nab-paclitaxel

  • Experimental
    VS-7375 + Pembrolizumab Dose Escalation

    To characterize the safety and tolerability of escalating doses of VS-7375 in combination with pembrolizumab and to determine the recommended phase 2 dose (RP2Ds) in patients with advanced or metastatic NSCLC harboring KRAS G12D-mutation.

    Drug: VS-7375 · Drug: Pembrolizumab

  • Experimental
    VS-7375 + Defactinib Dose Escalation

    To characterize the safety and tolerability of escalating doses of VS-7375 in combination with defactinib and to determine the recommended phase 2 dose (RP2Ds) in patients with advanced or metastatic NSCLC harboring KRAS G12D-mutation.

    Drug: VS-7375 · Drug: Defactinib

  • Experimental
    VS-7375 + Cetuximab Dose Expansion

    To evaluate the efficacy of VS-7375 in combination with cetuximab at the recommended phase 2 dose (RP2Ds) in patients with with advanced or metastatic CRC harboring KRAS G12D-mutation.

    Drug: VS-7375 · Drug: Cetuximab

  • Experimental
    VS-7375 + Carboplatin/Pemetrexed/Pembrolizumab Dose Expansion

    To evaluate the efficacy of VS-7375 in combination with carboplatin/pemetrexed/pembrolizumab at the recommended phase 2 dose (RP2Ds) in patients with metastatic NSCLC harboring KRAS G12D-mutation.

    Drug: VS-7375 · Drug: Carboplatin + Pemetrexed + Pembrolizumab

  • Experimental
    VS-7375 + Gemcitabine/Nab-Paclitaxel Dose Expansion

    To evaluate the efficacy of VS-7375 in combination with gemcitabine/nab-paclitaxel at the recommended phase 2 dose (RP2Ds) in patients with metastatic PDAC harboring KRAS G12D-mutation.

    Drug: VS-7375 · Drug: Gemcitabine + Nab-paclitaxel

  • Experimental
    VS-7375 + Midazolam and Repaglinide Drug-Drug Interaction

    To assess the drug-drug interaction of VS-7375 in combination with midazolam and repaglinide in patients with advanced or metastatic PDAC, NSCLC, and CRC harboring a KRAS G12D mutation.

    Drug: VS-7375 · Drug: Midazolam · Drug: Repaglinide

  • Experimental
    VS-7375 Serial Biopsy

    To characterize the preliminary anti-cancer activity of VS-7375 in participants with metastatic PDAC who have received 2 or 3 prior therapies, correlated with biopsy-obtained biomarkers.

    Drug: VS-7375

Interventions

  • VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D (ON/OFF) inhibitor.

  • Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR).

    Also known as: Erbitux

  • DrugCarboplatin + Pemetrexed + Pembrolizumab

    Drug pages: Carboplatin · Pemetrexed · Pembrolizumab

    A combination therapy regimen used as a first-line treatment for advanced non-squamous non-small cell lung cancer.

  • DrugGemcitabine + Nab-paclitaxel

    Drug pages: Gemcitabine · Albumin-Bound Paclitaxel

    A chemotherapy regimen used for the treatment of advanced or metastatic pancreatic ductal adenocarcinoma.

  • Immunotherapy used as a first-line treatment for advanced non-squamous non-small cell lung cancer.

  • A potent, selective, reversible inhibitor of focal adhesion kinase that also inhibits proline-rich tyrosine kinase-2

  • DrugMidazolam

    A short-acting benzodiazepine CNS depressant that has sedative, anxiolytic, amnesic, and hypnotic effects.

  • DrugRepaglinide

    A rapid-acting insulin secretagogue used to lower postprandial blood glucose in patients with type 2 diabetes mellitus.

06

What researchers measure

Primary outcomes

  1. Part A: To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375

    To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375 as monotherapy administered on a daily oral schedule in participants with any KRAS G12D-mutated solid tumor who have received 1 to 3 lines of prior systemic therapy. Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, and DLTs; and abnormal vital signs, physical examination, ECG parameters, ECOG PS, clinical laboratory results; and dose interruptions/reductions.

    Time frame: Up to 2.5 years

  2. Part A: To identify the MTD or MFD

    To identify the MTD or MFD using a BOIN design and recommend a dose for subsequent studies of VS-7375 as monotherapy on a daily oral schedule in participants with any KRAS G12D-mutated solid tumor who have received 1 to 3 lines of prior systemic therapy. Proportion/number of participants with DLTs during the DLT assessment period (C1D1 through C1D21).

    Time frame: Cycle 1 (each cycle is 21 days)

  3. Part B: To evaluate the preliminary anticancer activity of the optimal VS-7375 regimen

    To evaluate the efficacy of the optimal VS-7375 regimen identified from Part A in participants with metastatic KRAS G12D-mutated PDAC who have received 1 line of prior systemic therapy (cohort B1), NSCLC who have received 1 or 2 lines of prior systemic therapy (cohort B2), and other solid tumors who have received 1 or 2 lines of prior systemic therapy (cohort B3). Cohorts B1 and B2: Confirmed ORR by Investigator assessment per RECIST v1.1 . Cohort B3: Confirmed ORR by blinded independent central review (BICR) per RECIST v1.1.

    Time frame: Up to 2.5 years

  4. Part C: To characterize the safety, tolerability, and AE profile of VS-7375 in combination regimens.

    To characterize the safety, tolerability, and adverse event profile of VS-7375 in combination with: * Cetuximab in participants with advanced/metastatic PDAC after 1 prior systemic therapy, locally advanced/metastatic BTC after 1-2 prior systemic therapies, or metastatic CRC after 1-3 prior systemic therapies (C1) * Carboplatin, pembrolizumab, and pemetrexed in previously untreated metastatic NSCLC (C2) * Gemcitabine and nab-paclitaxel in locally advanced/metastatic PDAC after 1 prior systemic therapy (C3) * Pembrolizumab in locally advanced/metastatic NSCLC after up to 3 prior systemic therapies (C4) * Defactinib in metastatic PDAC or metastatic CRC (C5) Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, DLTs, and dose interruptions/reductions.

    Time frame: From enrollment to the end of treatment; an average of 9 months

  5. Part C: To identify a recommended dose for subsequent studies of combination dosed VS-7375.

    To identify a recommended dose for subsequent studies of combination dosed VS-7375. Proportion/number of participants with DLTs during the DLT assessment period (through end of Cycle 1).

    Time frame: Cycle 1 (each cycle is 21 or 28 days)

  6. Part D: To determine the preliminary anticancer activity of the optimal regimen of VS-7375 as identified in Part C

    To determine the efficacy of the optimal regimen of VS-7375 identified in Part C: * In combination with cetuximab in participants with metastatic colorectal adenocarcinoma who have received 1 to 3 prior lines of systemic therapy (cohort D1) * In combination with carboplatin, pembrolizumab, and pemetrexed in participants with previously untreated metastatic NSCLC (cohort D2) * In combination with gemcitabine and nab-paclitaxel in participants with previously untreated metastatic PDAC (cohort D3) Confirmed ORR by Investigator assessment, per RECIST v1.1 .

    Time frame: Up to 2.5 years

  7. Part E: To determine the impact of VS-7375 on the PK of midazolam or repaglinide

    AUC of midazolam, repaglinide and relative metabolites.

    Time frame: Up to 2.5 years

  8. Part E: To determine the impact of VS-7375 on the PK of midazolam or repaglinide

    Cmax of midazolam, repaglinide and relative metabolites.

    Time frame: 2.5 years

  9. Part E: To characterize the safety, tolerability, and AE profile of VS-7375 administered in combination with CYP3A4 and CYP2C8 substrates

    Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs and dose interruptions/reductions.

    Time frame: 2.5 years

  10. Part F: Serial biopsy

    To characterize the preliminary anti-cancer activity of VS-7375 in participants with metastatic PDAC, correlated with biopsy-obtained biomarkers.

    Time frame: Up to 2.5 years

Secondary outcomes

  1. Part A: To characterize the PK of VS-7375 as monotherapy administered on a daily oral schedule

    To characterize the PK of VS-7375 as monotherapy administered on a daily oral schedule in participants with any KRAS G12D-mutated solid tumor. PK parameters derived from plasma concentrations of VS-7375. Plasma Pharmacokinetics (PK) of VS-7375, Maximum concentration (Cmax) Plasma Pharmacokinetics (PK) of VS-7375, Area under plasma Concentration (AUC)

    Time frame: Up to 2.5 years

  2. Part A: To evaluate the preliminary anticancer activity of VS-7375 as monotherapy

    To evaluate the preliminary anticancer activity of VS-7375 as monotherapy in participants with any KRAS G12D-mutated solid tumor. Confirmed ORR, DCR, and DOR per RECIST v1.1 by Investigator assessments. Tumor response endpoints may also be evaluated using BICR assessments.

    Time frame: Up to 2.5 years

  3. Part B and D: To evaluate additional efficacy parameters of the recommended VS-7375 regimens from Part A and Part C

    To evaluate additional efficacy parameters of the recommended VS-7375 regimens from Part A (VS-7375 monotherapy) and Part C (VS-7375 in combination with other systemic therapies), administered on a daily oral schedule in participants with KRAS G12D-mutated solid tumors. Cohorts B1, B2, D1, D2 and D3: Confirmed ORR by BICR DOR, BoR, DCR, PFS per RECIST v1.1 and OS. Cohort B3: Confirmed ORR by Investigator assessment, DOR, BoR, DCR, PFS per RECIST v1.1 and OS.

    Time frame: Up to 2.5 years

  4. Parts B, C, D and F: To continue to evaluate the PK of VS-7375 as monotherapy and in combination with other systemic therapies

    Cmax of VS-7375

    Time frame: Up to 2.5 years

  5. Parts B, C, D and F: To continue to evaluate the PK of VS-7375 as monotherapy and in combination with other systemic therapies

    AUC of VS-7375

    Time frame: Up to 2.5 years

  6. Part C: To evaluate the preliminary anticancer activity of VS-7375 in combination with other systemic therapies

    Confirmed ORR per RECIST v1.1 by Investigator assessments. Tumor response endpoints may also be evaluated using BICR assessments.

    Time frame: Up to 2.5 years

  7. Part C: To evaluate the preliminary anticancer activity of VS-7375 in combination with other systemic therapies

    Confirmed DCR per RECIST v1.1 by Investigator assessments. Tumor response endpoints may also be evaluated using BICR assessments.

    Time frame: Up to 2.5 years

  8. Part C: To evaluate the preliminary anticancer activity of VS-7375 in combination with other systemic therapies

    Confirmed DOR per RECIST v1.1 by Investigator assessments. Tumor response endpoints may also be evaluated using BICR assessments.

    Time frame: Up to 2.5 years

  9. Parts B, and D: To characterize the safety, tolerability, of the recommended VS-7375 regimens from Part A and Part C

    To characterize the safety, tolerability, of the recommended VS-7375 regimens from Part A (VS-7375 monotherapy) and Part C (VS-7375 in combination with other systemic therapies), administered on a daily oral schedule in participants with KRAS G12D-mutated solid tumors. Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, and abnormal vital signs, physical examination, ECG parameters, ECOG PS, clinical laboratory results; and dose interruptions/reductions.

    Time frame: Up to 2.5 years

  10. Part C: Cohort C3: To evaluate the impact of VS-7375 on nab-paclitaxel

    Cmax of nab-paclitaxel

    Time frame: Up to 2.5 years

  11. Part C: Cohort C3: To evaluate the impact of VS-7375 on nab-paclitaxel

    AUC of nab-paclitaxel

    Time frame: Up to 2.5 years

07

Study locations

22 of 22 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2028, 42 months after the start.

Of 311 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 42 months is below that.

Counting every sponsor, half of 434 studies reached it within 62 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2025
First posted
Jun 13, 2025
StartActual
Jun 24, 2025
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added — first sites in France and Spain
Show 8 added (4 Spain, 3 France, 1 Australia)
  • Macquarie University · Sydney, Australia
  • Centre Leon Berard · Lyon, France
  • Centre d'Essais Precoces en Cancerologie de Marseille (CEPCM) · Marseille, France
  • Institut Curie · Paris, France
  • START Madrid - FJD · Madrid, Spain
  • START Madrid CIOCC - Hospital HM Sanchinarro · Madrid, Spain
  • Vall d'Hebron Instituto de Oncología · Barcelona, Spain
  • START Rioja - Hospital Universitario San Pedro · Logroño, Spain
across 3 updates, Oct 15, 2026 – Nov 10, 2026
Enrollment
295→616
Oct 15, 2026
Eligibility
1 criterion edited
What changed in the criteria
  • EditedHistory of treatment with direct and specific KRAS G12DRAS inhibitors.
Oct 15, 2026
Interventions
Added Drug: Pembrolizumab·Drug: Defactinib·Drug: Midazolam·Drug: Repaglinide; removed Drug: Gemcitabine. Arm changed VS-7375 Dose Escalation→VS-7375 Monotherapy Dose Escalation; Cetuximab + VS-7375 Dose Escalation→VS-7375 + Cetuximab Dose Escalation; VS-7375 Recommended Phase 2 Dose Expansion→VS-7375 Monotherapy Dose Expansion - PDAC; VS-7375 + Gemcitabine Dose Escalation→VS-7375 + Pembrolizumab Dose Escalation; VS-7375 + Gemcitabine Dose Expansion→VS-7375 Monotherapy Dose Expansion - NSCLC. Arms added: VS-7375 Monotherapy Dose Expansion - Solid Tumors·VS-7375 + Defactinib Dose Escalation·VS-7375 + Cetuximab Dose Expansion·VS-7375 + Midazolam and Repaglinide Drug-Drug Interaction·VS-7375 Serial Biopsy; arms removed: Cetuximab + VS-7375 Recommended Phase 2 Dose Expansion
Oct 15, 2026
Primary outcomes
4 added, 5 description edited
What changed in the outcomes
  • AddedPart E: To determine the impact of VS-7375 on the PK of midazolam or repaglinideTime frame: Up to 2.5 years
  • AddedPart E: To determine the impact of VS-7375 on the PK of midazolam or repaglinideTime frame: 2.5 years
  • AddedPart E: To characterize the safety, tolerability, and AE profile of VS-7375 administered in combination with CYP3A4 and CYP2C8 substratesTime frame: 2.5 years
  • AddedPart F: Serial biopsyTime frame: Up to 2.5 years
  • DescriptionPart A: To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375: how it is measured was reworded
  • DescriptionPart A: To identify the MTD or MFD: how it is measured was reworded
  • DescriptionPart B: To evaluate the preliminary anticancer activity of the optimal VS-7375 regimen: how it is measured was reworded
  • DescriptionPart C: To characterize the safety, tolerability, and AE profile of VS-7375 in combination regimens.: how it is measured was reworded
  • DescriptionPart D: To determine the preliminary anticancer activity of the optimal regimen of VS-7375 as identified in Part C: how it is measured was reworded
Oct 15, 2026
Secondary outcomes
5 edited, 6 added
What changed in the outcomes
  • EditedPart A: To characterize the PK of VS-7375 as 2L+ monotherapy administered on a daily oral scheduleTime frame: Up to 2.5 years
  • EditedPart A: To evaluate the preliminary anticancer activity of VS-737537375 as 2L+ monotherapyTime frame: Up to 2.5 years
  • EditedPartsPart B and D: To characterize the safety, tolerability, and AE profileevaluate additional efficacy parameters of the recommended VS-7375 regimens from Part A and Part CTime frame: Up to 2.5 years
  • EditedParts B, C, D and DF: To continue to evaluate the PK of VS-7375 as monotherapy and in combination with other systemic therapiesTime frame: Up to 2.5 years
  • EditedPart C: Cohort C3: To evaluate the impactpreliminary anticancer activity of VS-7375 on nab-paclitaxel PKin combination with other systemic therapiesTime frame: Up to 2.5 years
  • AddedParts B, C, D and F: To continue to evaluate the PK of VS-7375 as monotherapy and in combination with other systemic therapiesTime frame: Up to 2.5 years
  • AddedPart C: To evaluate the preliminary anticancer activity of VS-7375 in combination with other systemic therapiesTime frame: Up to 2.5 years
  • AddedPart C: To evaluate the preliminary anticancer activity of VS-7375 in combination with other systemic therapiesTime frame: Up to 2.5 years
  • AddedParts B, and D: To characterize the safety, tolerability, of the recommended VS-7375 regimens from Part A and Part CTime frame: Up to 2.5 years
  • AddedPart C: Cohort C3: To evaluate the impact of VS-7375 on nab-paclitaxelTime frame: Up to 2.5 years
  • AddedPart C: Cohort C3: To evaluate the impact of VS-7375 on nab-paclitaxelTime frame: Up to 2.5 years
Oct 15, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Virginia Mason Medical Center · Seattle, United StatesContact c•••@commonspirit.org · •••6272→p•••@commonspirit.org · •••6277
  • Cedars-Sinai Medical Center · Los Angeles, United StatesContact s•••@cshs.org→G•••@cshs.org · •••7855
  • Macquarie University · Sydney, AustraliaContact added s•••@mq.edu.au · •••3538
across 2 updates, Oct 15, 2026 – Oct 23, 2026
Show all 3 updates
  1. Nov 10, 2026
    2 sites added
    Show 2 added (2 Spain)
    • Vall d'Hebron Instituto de Oncología · Barcelona, Spain
    • START Rioja - Hospital Universitario San Pedro · Logroño, Spain
  2. Oct 23, 2026
    5 sites added — first sites in France and Spain
    Show 5 added (3 France, 2 Spain)
    • Centre Leon Berard · Lyon, France
    • Centre d'Essais Precoces en Cancerologie de Marseille (CEPCM) · Marseille, France
    • Institut Curie · Paris, France
    • START Madrid - FJD · Madrid, Spain
    • START Madrid CIOCC - Hospital HM Sanchinarro · Madrid, Spain
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Cedars-Sinai Medical Center · Los Angeles, United StatesContact s•••@cshs.org→G•••@cshs.org · •••7855
    • Macquarie University · Sydney, AustraliaContact added s•••@mq.edu.au · •••3538
  3. Oct 15, 2026
    1 site added
    Show site
    • Macquarie University · Sydney, Australia
    Enrollment 295→616
    Eligibility 1 criterion edited
    What changed in the criteria
    • EditedHistory of treatment with direct and specific KRAS G12DRAS inhibitors.
    Primary outcomes 4 added, 5 description edited
    What changed in the outcomes
    • AddedPart E: To determine the impact of VS-7375 on the PK of midazolam or repaglinideTime frame: Up to 2.5 years
    • AddedPart E: To determine the impact of VS-7375 on the PK of midazolam or repaglinideTime frame: 2.5 years
    • AddedPart E: To characterize the safety, tolerability, and AE profile of VS-7375 administered in combination with CYP3A4 and CYP2C8 substratesTime frame: 2.5 years
    • AddedPart F: Serial biopsyTime frame: Up to 2.5 years
    • DescriptionPart A: To characterize the safety, tolerability, and AE profile of escalating doses of VS-7375: how it is measured was reworded
    • DescriptionPart A: To identify the MTD or MFD: how it is measured was reworded
    • DescriptionPart B: To evaluate the preliminary anticancer activity of the optimal VS-7375 regimen: how it is measured was reworded
    • DescriptionPart C: To characterize the safety, tolerability, and AE profile of VS-7375 in combination regimens.: how it is measured was reworded
    • DescriptionPart D: To determine the preliminary anticancer activity of the optimal regimen of VS-7375 as identified in Part C: how it is measured was reworded
    Secondary outcomes 5 edited, 6 added
    What changed in the outcomes
    • EditedPart A: To characterize the PK of VS-7375 as 2L+ monotherapy administered on a daily oral scheduleTime frame: Up to 2.5 years
    • EditedPart A: To evaluate the preliminary anticancer activity of VS-737537375 as 2L+ monotherapyTime frame: Up to 2.5 years
    • EditedPartsPart B and D: To characterize the safety, tolerability, and AE profileevaluate additional efficacy parameters of the recommended VS-7375 regimens from Part A and Part CTime frame: Up to 2.5 years
    • EditedParts B, C, D and DF: To continue to evaluate the PK of VS-7375 as monotherapy and in combination with other systemic therapiesTime frame: Up to 2.5 years
    • EditedPart C: Cohort C3: To evaluate the impactpreliminary anticancer activity of VS-7375 on nab-paclitaxel PKin combination with other systemic therapiesTime frame: Up to 2.5 years
    • AddedParts B, C, D and F: To continue to evaluate the PK of VS-7375 as monotherapy and in combination with other systemic therapiesTime frame: Up to 2.5 years
    • AddedPart C: To evaluate the preliminary anticancer activity of VS-7375 in combination with other systemic therapiesTime frame: Up to 2.5 years
    • AddedPart C: To evaluate the preliminary anticancer activity of VS-7375 in combination with other systemic therapiesTime frame: Up to 2.5 years
    • AddedParts B, and D: To characterize the safety, tolerability, of the recommended VS-7375 regimens from Part A and Part CTime frame: Up to 2.5 years
    • AddedPart C: Cohort C3: To evaluate the impact of VS-7375 on nab-paclitaxelTime frame: Up to 2.5 years
    • AddedPart C: Cohort C3: To evaluate the impact of VS-7375 on nab-paclitaxelTime frame: Up to 2.5 years
    Interventions Added Drug: Pembrolizumab·Drug: Defactinib·Drug: Midazolam·Drug: Repaglinide; removed Drug: Gemcitabine. Arm changed VS-7375 Dose Escalation→VS-7375 Monotherapy Dose Escalation; Cetuximab + VS-7375 Dose Escalation→VS-7375 + Cetuximab Dose Escalation; VS-7375 Recommended Phase 2 Dose Expansion→VS-7375 Monotherapy Dose Expansion - PDAC; VS-7375 + Gemcitabine Dose Escalation→VS-7375 + Pembrolizumab Dose Escalation; VS-7375 + Gemcitabine Dose Expansion→VS-7375 Monotherapy Dose Expansion - NSCLC. Arms added: VS-7375 Monotherapy Dose Expansion - Solid Tumors·VS-7375 + Defactinib Dose Escalation·VS-7375 + Cetuximab Dose Expansion·VS-7375 + Midazolam and Repaglinide Drug-Drug Interaction·VS-7375 Serial Biopsy; arms removed: Cetuximab + VS-7375 Recommended Phase 2 Dose Expansion
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Virginia Mason Medical Center · Seattle, United StatesContact c•••@commonspirit.org · •••6272→p•••@commonspirit.org · •••6277
    + 2 other changes: index terms and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07020221
Lead sponsor
Verastem, Inc.
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
Jun 24, 2025
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Verastem Call Center
Contact
clinicaltrials@verastem.com
1 781 292 4204

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KRAS G12D Inhibitor VS-7375

Start the discussion